GlaxoSmithKline Zyban
Executive Summary
A modified dosing schedule for bupropion is implemented by the U.K. Medicines Control Agency May 30 following reports of seizures. Over 419,000 patients have been treated in the U.K. and 126 seizures have been reported. In about 50% of the cases, patients had predisposing factors for seizure. The MCA is recommending that Zyban should be dosed at 150 mg once daily for the first six days of treatment before switching to twice daily on day seven. In the U.S., patients are switched to twice daily dosing on day four
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth